Novartis to Take 15% of Gamida Cell Plus Option to Buy Rest

Deal value for developer of stem-cell therapies, including milestone payments, could surpass $600 million.

comments Print
In a stunning turnaround from an apparently failed deal last spring, Swiss drugmaker Novartis agreed to take a stake in Gamida Cell, a developer of stem-cell therapies, in a deal that could reach a value of...